ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. ABILIFY is indicated for the treatment of
Bipolar maintenance [monotherapy (Abilify, Abilify Maintena) and adjunct (Abilify)] Oral aripiprazole as maintenance treatment in adolescent schizophrenia
ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. ABILIFY is indicated for the treatment of moderate
Commonly observed adverse reactions associated with the use of ABILIFY in adolescent patients with schizophrenia (incidence of 5% or greater and ABILIFY
ABILIFY is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. ABILIFY is indicated for the treatment of moderate
Adolescents. The recommended target dose of ABILIFY is 10 mg/day. Aripiprazole was studied in adolescent patients 13 to 17 years of age with
Commonly observed adverse reactions associated with the use of ABILIFY in adolescent patients with schizophrenia (incidence of 5% or greater and ABILIFY
Commonly observed adverse reactions associated with the use of ABILIFY in adolescent patients with schizophrenia (incidence of 5% or greater and ABILIFY
by B DIOMäINA Cited by 6Aripiprazole (Abilify) is an atypical antipsy- chotic partial agonist at ARIPIPRAZOLE (ABILIFY) IN CHILDREN AND ADOLESCENTS. AT THE CHILD AND
Comments